FNDC5/Irisin in dementia and cognitive impairment: update and novel perspective

Epidemiological surveys show that the incidence of age-related dementia and cognitive impairment is increasing and it has been a heavy burden for society, families, and healthcare systems, making the preservation of cognitive function in an increasingly aging population a major challenge. Exercise i...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian journal of medical and biological research 2024-01, Vol.57, p.e13447
Main Authors: Guo, Xiaofeng, Huang, Xiaocheng, Yang, Yachao, Dong, Luying, Kong, Dehuan, Zhang, Jianmei
Format: Article
Language:English
Subjects:
Adenylate kinase
Aging
Alzheimer's disease
BIOLOGY
Care and treatment
Cognition disorders
Cognitive ability
Cognitive Dysfunction - etiology
Cognitive impairment
Dementia
Dementia disorders
Epidemiology
FDNC5/irisin
Fibronectins - metabolism
Health aspects
Humans
Medical colleges
Medical research
Medicine, Experimental
MEDICINE, RESEARCH & EXPERIMENTAL
Muscles
Parkinson's disease
Physiological aspects
Review
Skeletal muscle
Surveys
Vascular dementia
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epidemiological surveys show that the incidence of age-related dementia and cognitive impairment is increasing and it has been a heavy burden for society, families, and healthcare systems, making the preservation of cognitive function in an increasingly aging population a major challenge. Exercise is beneficial for brain health, and FDNC5/irisin, a new exercise-induced myokine, is thought to be a beneficial mediator to cognitive function and plays an important role in the crosstalk between skeletal muscle and brain. This review provides a critical assessment of the recent progress in both fundamental and clinical research of FDNC5/irisin in dementia and cognitive impairment-related disorders. Furthermore, we present a novel perspective on the therapeutic effectiveness of FDNC5/irisin in alleviating these conditions.
ISSN:0100-879X
1414-431X
1414-431X
1678-4510
DOI:10.1590/1414-431X2024e13447